

# Filippo Baldacci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6583598/publications.pdf>

Version: 2024-02-01

112  
papers

2,788  
citations

201674

27  
h-index

206112

48  
g-index

115  
all docs

115  
docs citations

115  
times ranked

4454  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	4.8	201
2	Cognitive and neuroimaging features and brain $\beta$ -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	10.2	161
3	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 601-606.	1.9	130
4	Revolution of Alzheimer Precision Neurology. <i>Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease</i> , 2018, 64, S47-S105.	2.6	122
5	Plasma amyloid $\beta$ 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.8	122
6	Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study. <i>Scientific Reports</i> , 2017, 7, 39471.	3.3	108
7	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: $A\beta_{42}$ , total $\tau$ , phosphorylated $\tau$ , NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.8	91
8	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 691-694.	1.4	79
9	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	7.1	79
10	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	3.0	78
11	Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. <i>Human Brain Mapping</i> , 2014, 35, 3932-3944.	3.6	75
12	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021, 69, 101346.	10.9	74
13	$\beta$ -Synuclein Heterocomplexes with $\beta$ -Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 53.	2.9	51
14	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	3.1	48
15	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	3.8	46
16	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 522-526.	2.2	45
17	Association of cerebrospinal fluid $\beta$ -synuclein with total and phosphorylated $\tau_{181}$ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631.	0.8	45
18	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950.	0.8	43

#	ARTICLE	IF	CITATIONS
19	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2020, 20, 421-441.	3.1	42
20	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Review of Proteomics, 2019, 16, 593-600.	3.0	41
21	Migraine features in migraineurs with and without anxietyâ€“depression symptoms: A hospital-based study. Clinical Neurology and Neurosurgery, 2015, 132, 74-78.	1.4	40
22	Twoâ€“level diagnostic classification using cerebrospinal fluid YKLâ€“40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.8	39
23	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	2.6	35
24	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. Molecular Neurobiology, 2020, 57, 4667-4691.	4.0	33
25	Î±-Synuclein Aggregates with Î²-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects. Molecular Neurobiology, 2018, 55, 2653-2675.	4.0	32
26	Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Parkinsonism and Related Disorders, 2014, 20, 671-672.	2.2	31
27	Decreased and increased cortical activation coexist in de novo Parkinson's disease. Experimental Neurology, 2010, 224, 299-306.	4.1	30
28	Impact of <sc>Coronavirus Disease 20</sc>19 Pandemic on Cognition in Parkinson's Disease. Movement Disorders, 2020, 35, 1717-1718.	3.9	30
29	Hypoactivation of the primary sensorimotor cortex in de novo Parkinsonâ€™s disease. Neuroradiology, 2012, 54, 261-268.	2.2	29
30	Fatigue, sleepâ€“wake pattern, depressive and anxiety symptoms and body-mass index: analysis in a sample of episodic and chronic migraine patients. Neurological Sciences, 2016, 37, 987-989.	1.9	28
31	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081.	4.1	27
32	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 124-131.	1.3	26
33	Clinical features associated with ictal osmophobia in migraine. Neurological Sciences, 2015, 36, 43-46.	1.9	26
34	Triggers in Allodynic and Nonâ€“Allodynic Migraineurs. A Clinic Setting Study. Headache, 2013, 53, 152-160.	3.9	25
35	Nummular headache dramatically responsive to indomethacin. Cephalalgia, 2010, 30, 1151-1152.	3.9	24
36	Potential Diagnostic Value of Red Blood Cells Î±-Synuclein Heteroaggregates in Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 6451-6459.	4.0	24

#	ARTICLE	IF	CITATIONS
37	How Aware Are Migraineurs of Their Triggers?. <i>Headache</i> , 2013, 53, 834-837.	3.9	23
38	Reliability of administrative data for the identification of Parkinson's disease cohorts. <i>Neurological Sciences</i> , 2015, 36, 783-786.	1.9	23
39	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147.	6.2	23
40	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , 2016, 5, 383-387.	6.5	22
41	Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer's disease. <i>Endocrine</i> , 2017, 55, 981-984.	2.3	21
42	Spontaneous bilateral carotid artery dissection and hereditary haemochromatosis: what relationship?. <i>Neurological Sciences</i> , 2006, 27, 291-292.	1.9	20
43	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <i>Journal of Personalized Medicine</i> , 2020, 10, 221.	2.5	20
44	Indotest in Atypical Hemigrania Continua. <i>Cephalalgia</i> , 2008, 28, 300-301.	3.9	18
45	Î±-Synuclein Aggregated with Tau and Î²-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 17.	3.4	18
46	Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine. <i>Toxins</i> , 2019, 11, 608.	3.4	18
47	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	3.1	18
48	Postpartum Headache Due to Spontaneous Cervical Artery Dissection. <i>Headache</i> , 2011, 51, 809-813.	3.9	17
49	A single center study: AÎ²42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. <i>Neurological Sciences</i> , 2017, 38, 1791-1797.	1.9	16
50	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020, 17, 543-559.	3.0	16
51	Epilepsy occurrence in patients with Alzheimer's disease: clinical experience in a tertiary dementia center. <i>Neurological Sciences</i> , 2016, 37, 645-647.	1.9	15
52	Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 35-41.	1.9	15
53	fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 265-268.	2.2	14
54	Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1313-1314.	2.2	14

#	ARTICLE	IF	CITATIONS
55	Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinson's Disease Patients. <i>Genes</i> , 2021, 12, 720.	2.4	14
56	Prevalence of right-to-left shunt in patients with cluster headache. <i>Journal of Headache and Pain</i> , 2005, 6, 244-246.	6.0	13
57	Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome. <i>Neurological Sciences</i> , 2013, 34, 1893-1896.	1.9	13
58	Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medication Overuse Headache. <i>Headache</i> , 2015, 55, 984-991.	3.9	13
59	Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. <i>Functional Neurology</i> , 2015, 30, 119-23.	1.3	13
60	~Airplane headache~™ with aura. <i>Cephalalgia</i> , 2010, 30, 624-625.	3.9	12
61	Peri-ictal prolonged atrial fibrillation after generalized seizures: Description of a case and etiopathological considerations. <i>Epilepsy and Behavior</i> , 2012, 23, 377-378.	1.7	12
62	Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1290-1292.	2.2	12
63	A frontline defense against neurodegenerative diseases: the development of early disease detection methods. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 559-563.	3.1	12
64	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.9	12
65	CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 4586.	2.4	12
66	Bilateral Thalamic Infarct Caused by Spontaneous Vertebral Artery Dissection in Pre-eclampsia with HELLP Syndrome: A Previously Unreported Association. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 914.e9-914.e10.	1.6	11
67	Impact of ApoE Polymorphism and Physical Activity on Plasma Antioxidant Capability and Erythrocyte Membranes. <i>Antioxidants</i> , 2019, 8, 538.	5.1	11
68	Apolipoprotein E Polymorphism and Oxidative Stress in Human Peripheral Blood Cells: Can Physical Activity Reactivate the Proteasome System through Epigenetic Mechanisms?. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-16.	4.0	11
69	The ~Closing-In~ Phenomenon in Parkinson's Disease Dementia and Lewy-Body Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, E38-E39.	1.8	10
70	Cerebellar Ataxia with Complete Clinical Recovery and Resolution of MRI Lesions Related to Central Pontine Myelinolysis: Case Report and Literature Review. <i>Case Reports in Neurology</i> , 2010, 2, 157-162.	0.7	9
71	Localized Calcific Hematoma of the Scalp Presenting as a Nummular~ Like Headache. A Case Report. <i>Headache</i> , 2014, 54, 370-372.	3.9	9
72	±-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	2.6	9

#	ARTICLE	IF	CITATIONS
73	Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5393.	4.1	9
74	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	3.0	8
75	Locus Coeruleus magnetic resonance imaging in cognitively intact elderly subjects. <i>Brain Imaging and Behavior</i> , 2021, , 1.	2.1	8
76	SUNA Syndrome With Seasonal Pattern. <i>Headache</i> , 2009, 49, 912-914.	3.9	6
77	A case of idiopathic low CSF pressure headache presenting as cough headache. <i>Neurological Sciences</i> , 2010, 31, 789-791.	1.9	6
78	Supersaturation of VEP in Migraine without Aura Patients Treated with Topiramate: An Anatomico-Functional Biomarker of the Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 769.	2.4	6
79	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.8	5
80	A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy. <i>Neurological Sciences</i> , 2014, 35, 1603-1605.	1.9	4
81	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	2.8	4
82	Donepezil improves vascular function in a mouse model of Alzheimer's disease. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00871.	2.4	4
83	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. <i>Diagnostics</i> , 2022, 12, 796.	2.6	4
84	Î±-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 411-425.	3.1	4
85	Vertebrobasilar Recording with Contrast Transcranial Doppler in Right-to-Left Shunt Diagnosis. <i>Cerebrovascular Diseases</i> , 2008, 26, 569-569.	1.7	3
86	Progressive Impairment of Decision-Making in Behavioral-Variant Frontotemporal Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E20-E21.	1.8	3
87	Sexual headache: two familiar orgasmic headache cases and review of the literature. <i>Acta Neurologica Belgica</i> , 2015, 115, 757-758.	1.1	2
88	RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome"; <i>Parkinsonism and Related Disorders</i> , 2015, 21, 427.	2.2	2
89	Ageing and sex impact plasma NFL and τ trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792.	0.8	2
90	Dopamine Agonist Modifies Cortical Activity in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2014, 37, 166-172.	0.7	1

#	ARTICLE	IF	CITATIONS
91	P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience. Journal of Headache and Pain, 2015, 16, A113.	6.0	1
92	P041. Analysis of body mass index, psychiatric comorbidity, sleep-wake pattern and occurrence of fatigue in episodic and chronic migraine patients. Journal of Headache and Pain, 2015, 16, A188.	6.0	1
93	Spontaneous Dorsal Extramedullary Hematoma: A Rare Case Presenting as Isolated Thunderclap Headache. Headache, 2015, 55, 1263-1265.	3.9	1
94	Chronic Migraine With Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol. Headache, 2016, 56, 402-403.	3.9	1
95	P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: AÎ²<sub>1â€42</sub>, TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154.	0.8	1
96	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. Journal of Alzheimer's Disease, 2021, 84, 757-766.	2.6	1
97	Gestural buffer impairment in early onset Corticobasal Degeneration: a single-case study. Neuropsychological Trends (discontinued), 2008, , .	0.6	1
98	Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease. Clinical Neurology and Neurosurgery, 2013, 115, 1105-1106.	1.4	0
99	[P1â€281]: DIAGNOSTIC PERFORMANCE USING CSF YKLâ€40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P357.	0.8	0
100	[P2â€262]: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHTâ€PREAD STUDY. Alzheimer's and Dementia, 2017, 13, P713.	0.8	0
101	[O4â€02â€05]: UNBIASED BIOMARKERâ€BASED CATEGORIZATION OF A MULTICENTER COHORT OF ADD, MCI AND FTD PATIENTS. Alzheimer's and Dementia, 2017, 13, P1231.	0.8	0
102	Head tremor as a warning symptom of rapidly progressive syringomyelia: a case report. Neurological Sciences, 2018, 39, 1497-1499.	1.9	0
103	P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.	0.8	0
104	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036.	0.8	0
105	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	0.8	0
106	P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767.	0.8	0
107	Red blood cell Î±â€synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the ADâ€LBD spectrum. Alzheimer's and Dementia, 2020, 16, e040618.	0.8	0
108	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Sex differences in red blood cell $\alpha$ -synuclein protein and its heteroaggregates with amyloid $\beta$ and tau in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042079.	0.8	0
110	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer's disease and other types of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043616.	0.8	0
111	Atypical Hyperperfusion Encephalopathy in Post-Carotid Stenting. <i>Scholarly Research Exchange</i> , 2009, 2009, 1-2.	0.2	0
112	Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 352-353.	1.8	0